TY - JOUR T1 - Partial lockdown on unvaccinated individuals promises breaking of fourth COVID-19 wave in Bavaria JF - medRxiv DO - 10.1101/2021.11.28.21266959 SP - 2021.11.28.21266959 AU - Tobias Krebs AU - Michael J. Moeckel Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/29/2021.11.28.21266959.abstract N2 - Purpose of this report The aim of this rapid communication is a projection of the development of the fourth COVID-19 wave in the federal state of Bavaria in Germany, taking into account different lockdown scenarios especially for unvaccinated individuals. In particular, the number of infections and the occupancy of intensive care facilities are considered.Applied Methods We use the agent-based epidemiological simulator Covasim for discussing various epidemiological scenarios. Firstly, we adapt and calibrate our model to reproduce the historical course of the COVID-19 pandemic in Bavaria. For this, we model and integrate numerous public health interventions imposed on the local population. As for some of the political actions rigorous quantification is currently not available, we fit those unknown (free) model parameters to published data on the measured epidemiological dynamics. Finally, we define and analyse scenarios of different lockdown scenarios with restrictions for unvaccinated individuals in different areas of life.Key message The results of our simulations show that in all scenarios considered, the number of infections, but also the number of severe cases, exceed previous maximum values. Interventions, especially restrictions on contacts of unvaccinated persons, can still mitigate the impact of the fourth COVID-19 wave on populations substantially. Excluding unvaccinated students from attending classes has only a small impact on the public health burden. However, many severe cases can be prevented by reducing community and/or work related contacts of unvaccinated people, e.g, by achieving high home office rates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors gratefully acknowledge funding by the EpiLABKI project through the Bavarian Programme for Applied Research and Development at Universities of Applied Sciences (6th funding period).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOnly data from publicly available sources has been used. ER -